placebo-controlled studies. Nonetheless, amiodarone is approved for use against VT and
VF by most regulatory agencies worldwide and has a high profile as a useful drug. 21 Its …

Abstract Between 1977 and 1986, 589 patients (age, 57±13 years; 464 men and 125
women) received amiodarone for ventricular fibrillation (VF; 147 patients), sustained (VT-S; …

Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular
tachycardia (VT)(n= 118) or a cardiac arrest (n= 36) and who were refractory to conventional …

Amiodarone, a complex compound with variegated electropharmacologic and
pharmacokinetic properties and an equally complex side-effect profile, continues to have a …

The clinical antiarrhythmic efficacy of amiodarone treatment was examined in 196 patients
with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) resistant to other …

The efficacy and safety of long-term oral amiodarone was assessed in 173 patients with
symptomatic tachyarrhythmias: 96 with life-threatening ventricular tachycardia and fibrillation …

Four hundred sixty-two patients, all with either documented spontaneous sustained
ventricular tachycardia or cardiac arrest unresponsive to other antiarrhythmic drugs …

The effects of amiodarone in a low dosage (200 mg every 8 h for 2 weeks, then 200 mg/day)
was assessed in a double-blind placebo-controlled trial in 34 patients with a history of …

Arrhythmias may be controlled in most patients with recurrent supraventricular tachycardia
or atrial fibrillation with small to moderate maintenance doses of amiodarone (100 to 400 …

Background Asymptomatic ventricular arrhythmias in patients with congestive heart failure
are associated with increased rates of overall mortality and sudden death. Amiodarone is …